Comparative safety of Pfizer-BioNTech COVID-19 vaccine vs non–SARS-CoV-2 vaccines in children younger than age 5

About The Study: The symptoms reported after administration of the Pfizer-BioNTech COVID-19 vaccine were comparable overall to those for approved non–SARS-CoV-2 vaccines in this study including 7,800 children younger than age 5. The data may be used together with prospective licensure studies of BNT162b2 efficacy and safety and could help guide expert recommendations about BNT162b2 vaccinations in this age group.

Authors: Cho-Ming Chao, M.D., Ph.D., of the University of Rostock in Rostock, Germany, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamanetworkopen.2022.37140)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetJAMA Network Openworkopen/fullarticle/10.1001/jamanetworkopen.2022.37140?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=101822

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.